Biobot Surgical

Biobot Surgical operates in the medical technology sector, specializing in robotic systems for prostate biopsies. The company's flagship product, the iSR'obot Mona Lisa, is a robotic transperineal prostate biopsy system that integrates MRI and ultrasound fusion technology. This system is designed to provide physicians with complete prostate coverage and accurate biopsy needle positioning, enhancing both precision and ease of use. The primary clients are healthcare providers, including hospitals and specialized clinics, who require advanced tools for diagnosing prostate cancer. Biobot Surgical's business model revolves around the sale and distribution of its robotic systems, along with associated software and support services. Revenue is generated through direct sales, distributorship agreements, and ongoing service contracts. The market for Biobot Surgical's products is global, with a focus on regions with high incidences of prostate cancer and advanced healthcare infrastructure.

Keywords: robotic biopsy, prostate cancer, MRI fusion, ultrasound, transperineal, precision medicine, healthcare technology, medical devices, diagnostic tools, clinical outcomes.